Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2008

To view an abstract, select an author from the vertical list on the left side.

2008 Grants - Marr

Investigation of the Role of MMEL in Protection from Alzheimer's Disease

Robert A. Marr, Ph.D.
Rosalind Franklin University of Medicine and Science
North Chicago, Illinois

2008 New Investigator Research Grant

Amyloid plaques, a characteristic feature of Alzheimer pathology, are constructed of large aggregates of beta-amyloid, a protein fragment found in the brain. It has been suggested that increasing the ability of the brain to clear beta-amyloid may be a useful approach to slowing or halting progression of the disease.

One enzyme that degrades beta-amyloid in the human brain has already been characterized. A second beta-amyloid-degrading enzyme has been described in mice. Blocking the expression of this gene in mice causes increases in beta-amyloid levels in the brain. Robert A. Marr, Ph.D., and colleagues are characterizing the human version of this second enzyme, named membrane metallo-endopeptidase-like protein (MMEL). They have already shown that one version of MMEL (MMELb) is able to degrade beta-amyloid.

Dr. Marr and colleagues plan to extend their studies of MMEL to understand its role in Alzheimer's disease. They will quantify the expression of different versions of MMEL in human brain samples from healthy individuals and from individuals with Alzheimer's disease. The researchers will also genetically engineer mice to express high levels of MMELb to determine if such treatment reduces accumulation of beta-amyloid and preserves cognitive function. These studies may improve our understanding of how beta-amyloid is degraded, and they may suggest opportunities for the development of new treatment strategies for Alzheimer's disease.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.